Literature DB >> 25110433

CacyBP/SIP nuclear translocation induced by gastrin promotes gastric cancer cell proliferation.

Hui-Hong Zhai1, Juan Meng1, Jing-Bo Wang1, Zhen-Xiong Liu1, Yuan-Fei Li1, Shan-Shan Feng1.   

Abstract

AIM: To investigate the role of nuclear translocation of calcyclin binding protein, also called Siah-1 interacting protein (CacyBP/SIP), in gastric carcinogenesis.
METHODS: The expression of CacyBP/SIP protein in gastric cancer cell lines was detected by Western blot. Immunofluorescence experiments were performed on gastric cancer cell lines that had been either unstimulated or stimulated with gastrin. To confirm the immunofluorescence findings, the relative abundance of CacyBP/SIP in nuclear and cytoplasmic compartments was assessed by Western blot. The effect of nuclear translocation of CacyBP/SIP on cell proliferation was examined using MTT assay. The colony formation assay was used to measure clonogenic cell survival. The effect of CacyBP/SIP nuclear translocation on cell cycle progression was investigated. Two CacyBP/SIP-specific siRNA vectors were designed and constructed to inhibit CacyBP/SIP expression in order to reduce the nuclear translocation of CacyBP/SIP, and the expression of CacyBP/SIP in stably transfected cells was determined by Western blot. The effect of inhibiting CacyBP/SIP nuclear translocation on cell proliferation was then assessed.
RESULTS: CacyBP/SIP protein was present in most of gastric cancer cell lines. In unstimulated cells, CacyBP/SIP was distributed throughout the cytoplasm; while in stimulated cells, CacyBP/SIP was found mainly in the perinuclear region. CacyBP/SIP nuclear translocation generated a growth-stimulatory effect on cells. The number of colonies in the CacyBP/SIP nuclear translocation group was significantly higher than that in the control group. The percentage of stimulated cells in G1 phase was significantly lower than that of control cells (69.70% ± 0.46% and 65.80% ± 0.60%, control cells and gastrin-treated SGC7901 cells, P = 0.008; 72.99% ± 0.46% and 69.36% ± 0.51%, control cells and gastrin-treated MKN45 cells, P = 0.022). CacyBP/SIPsi1 effectively down-regulated the expression of CacyBP/SIP, and cells stably transfected by CacyBP/SIPsi1 were then chosen for further cellular assays. In CacyBP/SIPsi1 stably transfected cells, CacyBP/SIP was shown to be distributed throughout the cytoplasm, irregardless of whether they were stimulated or not. After CacyBP/SIP nuclear translocation was reduced, there had no major effect on cell proliferation, as shown by MTT assay. There had no enhanced anchorage-dependent growth upon stimulation, as indicated by colony formation in flat plates. No changes appeared in the percentage of cells in G0-G1 phase in either cell line (71.09% ± 0.16% and 70.86% ± 0.25%, control cells and gastrin-treated SGC7901-CacyBP/SIPsi1 cells, P = 0.101; 74.17% ± 1.04% and 73.07% ± 1.00%, control cells and gastrin-treated MKN45-CacyBP/SIPsi1 cells, P = 0.225).
CONCLUSION: CacyBP/SIP nuclear translocation promotes the proliferation and cell cycle progression of gastric cancer cells.

Entities:  

Keywords:  Calcyclin binding protein/Siah-1 interacting protein; Gastric caner cells; Gastrin; Nuclear translocation

Mesh:

Substances:

Year:  2014        PMID: 25110433      PMCID: PMC4123335          DOI: 10.3748/wjg.v20.i29.10062

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses.

Authors:  S I Matsuzawa; J C Reed
Journal:  Mol Cell       Date:  2001-05       Impact factor: 17.970

2.  Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint.

Authors:  Toru Fukushima; Juan M Zapata; Netai C Singha; Michael Thomas; Christina L Kress; Maryla Krajewska; Stan Krajewski; Ze'ev Ronai; John C Reed; Shu-Ichi Matsuzawa
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

3.  Molecular cloning and expression of a mouse brain cDNA encoding a novel protein target of calcyclin.

Authors:  A Filipek; J Kuźnicki
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

4.  CacyBP/SIP protein promotes proliferation and G1/S transition of human pancreatic cancer cells.

Authors:  Xiong Chen; Ping Mo; Xiaohua Li; Peichan Zheng; Lina Zhao; Zengfu Xue; Gui Ren; Guohong Han; Xin Wang; Daiming Fan
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

5.  Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma.

Authors:  Shiren Sun; Xiaoxuan Ning; Jie Liu; Lili Liu; Yu Chen; Shuang Han; Yanqi Zhang; Jie Liang; Kaichun Wu; Daiming Fan
Journal:  Biochem Biophys Res Commun       Date:  2007-03-26       Impact factor: 3.575

6.  Establishment and characterization of calcyclin binding protein (CacyBP) monoclonal antibody.

Authors:  Huihong Zhai; Yongquan Shi; Jinhua Yu; Liu Hong; Hongwei Tang; Jun Wang; Shengjuan Hu; Feihu Bai; Daiming Fan
Journal:  Hybridoma (Larchmt)       Date:  2006-04

7.  Regulation of drug sensitivity of gastric cancer cells by human calcyclin-binding protein (CacyBP).

Authors:  Yongquan Shi; Wenhua Hu; Fang Yin; Li Sun; Changjiang Liu; Mei Lan; Daiming Fan
Journal:  Gastric Cancer       Date:  2004       Impact factor: 7.370

8.  Coupling of pancreatic gastrin/cholecystokinin-B (G/CCKB) receptors to phospholipase C and protein kinase C in AR4-2J tumoral cells.

Authors:  C Seva; J L Scemama; L Pradayrol; P D Sarfati; N Vaysse
Journal:  Regul Pept       Date:  1994-06-16

9.  Translocation and phosphorylation of calcyclin binding protein during retinoic acid-induced neuronal differentiation of neuroblastoma SH-SY5Y cells.

Authors:  Jing Wu; Xinyu Tan; Xiaozhong Peng; Jiangang Yuan; Boqin Qiang
Journal:  J Biochem Mol Biol       Date:  2003-07-31

10.  Inhibition of gastrin-induced proliferation of AR4-2J cells by calcium channel antagonists.

Authors:  V Bertrand; M J Bastié; N Vaysse; L Pradayrol
Journal:  Int J Cancer       Date:  1994-02-01       Impact factor: 7.396

View more
  7 in total

1.  Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.

Authors:  Yan Cui; Shao-Bo Li; Xing-Chun Peng; Jun Wu; Guo-Hui Fu
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

Review 2.  The potential role of CacyBP/SIP in tumorigenesis.

Authors:  Xiaoxuan Ning; Yang Chen; Xiaosu Wang; Qiaoneng Li; Shiren Sun
Journal:  Tumour Biol       Date:  2016-02-13

3.  CacyBP/SIP nuclear translocation regulates p27Kip1 stability in gastric cancer cells.

Authors:  Ying-Lin Niu; Ya-Jun Li; Jing-Bo Wang; Yuan-Yuan Lu; Zhen-Xiong Liu; Shan-Shan Feng; Jian-Guo Hu; Hui-Hong Zhai
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

4.  CacyBP/SIP promotes the proliferation of colon cancer cells.

Authors:  Huihong Zhai; Yongquan Shi; Xiong Chen; Jun Wang; Yuanyuan Lu; Faming Zhang; Zhengxiong Liu; Ting Lei; Daiming Fan
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

5.  The effect of S100A6 on nuclear translocation of CacyBP/SIP in colon cancer cells.

Authors:  Shanshan Feng; Qiaozhi Zhou; Bo Yang; Qianqian Li; Aiqin Liu; Yingying Zhao; Changqing Qiu; Jun Ge; Huihong Zhai
Journal:  PLoS One       Date:  2018-03-13       Impact factor: 3.240

6.  Newcastle Disease Virus V Protein Inhibits Cell Apoptosis and Promotes Viral Replication by Targeting CacyBP/SIP.

Authors:  Zhili Chu; Caiying Wang; Qiuxia Tang; Xiaolei Shi; Xiaolong Gao; Jiangang Ma; Kejia Lu; Qingsong Han; Yanqing Jia; Xiangwei Wang; Fathalrhman Eisa Addoma Adam; Haijin Liu; Sa Xiao; Xinglong Wang; Zengqi Yang
Journal:  Front Cell Infect Microbiol       Date:  2018-09-03       Impact factor: 5.293

7.  Gastrin Enhances Autophagy and Promotes Gastric Carcinoma Proliferation via Inducing AMPKα.

Authors:  Zhuang Kun; Guo Hanqing; Tang Hailing; Yan Yuan; Zhang Jun; Zhang Lingxia; Han Kun; Zhang Xin
Journal:  Oncol Res       Date:  2017-01-05       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.